Evidence map›Paper›PMID 26112001›Full record

ArticleEuropean urology2016

Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.

Xiaosong Meng, Andrew B Rosenkrantz, Neil Mendhiratta, Michael Fenstermaker, Richard Huang, James S Wysock, Marc A Bjurlin, Susan Marshall, Fang-Ming Deng, Ming Zhou and 4 more

Registry-linked trialAbstract readComparative Study
In one paragraph

Article in European urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02799303 (A Randomized Clinical Trial Comparing the Efficacy of MRI Versus PSA for Prostate Cancer Screening), which is not on this map. Cited by 76 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 3 pooled it
26.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02799303 naunknown statusnot on this map

A Randomized Clinical Trial Comparing the Efficacy of MRI Versus PSA for Prostate Cancer Screening: The MVP Study (MRI vs PSA)

TypeinterventionalSponsorSunnybrook Health Sciences CentreRan2016 to 2020Enrolled1,010ConditionsProstate CancerArmsMulti-parametric MRI, PSA testing
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 3 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. [PREFERE - Study on the rise].Der Urologe. Ausg. A · 2016
    Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Axumin (World journal of urology · 2022
    Article
  18. Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Xiaosong MengDepartment of Urology, NYU Langone Medical Center, New York, NY, USA.
Andrew B RosenkrantzDepartment of Radiology, NYU Langone Medical Center, New York, NY, USA.
Neil MendhirattaSchool of Medicine, NYU Langone Medical Center, New York, NY, USA.
Michael FenstermakerSchool of Medicine, NYU Langone Medical Center, New York, NY, USA.
Richard HuangDepartment of Urology, NYU Langone Medical Center, New York, NY, USA.
James S WysockDepartment of Urology, NYU Langone Medical Center, New York, NY, USA; Department of Urology, New York Hospital Queens, Flushing, NY, USA.
Marc A BjurlinDepartment of Urology, NYU Langone Medical Center, New York, NY, USA; Department of Urology, St. Barnabas Hospital, Bronx, NY, USA.
Susan MarshallDepartment of Urology, NYU Langone Medical Center, New York, NY, USA.
Fang-Ming DengDepartment of Pathology, NYU Langone Medical Center, New York, NY, USA.
Ming ZhouDepartment of Pathology, NYU Langone Medical Center, New York, NY, USA.
Jonathan MelamedDepartment of Pathology, NYU Langone Medical Center, New York, NY, USA.
William C HuangDepartment of Urology, NYU Langone Medical Center, New York, NY, USA.
Herbert LeporDepartment of Urology, NYU Langone Medical Center, New York, NY, USA.
Samir S TanejaDepartment of Urology, NYU Langone Medical Center, New York, NY, USA; Department of Radiology, NYU Langone Medical Center, New York, NY, USA. Electronic address: samir.taneja@nyumc.org.
NYU Langone Health · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
NCI NIH HHS P30 CA016087
6 · The paper itself

Abstract

backgroundIncreasing evidence supports the use of magnetic resonance imaging (MRI)-ultrasound fusion-targeted prostate biopsy (MRF-TB) to improve the detection of clinically significant prostate cancer (PCa) while limiting detection of indolent disease compared to systematic 12-core biopsy (SB).

objectiveTo compare MRF-TB and SB results and investigate the relationship between biopsy outcomes and prebiopsy MRI. DESIGN, SETTING, AND

participantsRetrospective analysis of a prospectively acquired cohort of men presenting for prostate biopsy over a 26-mo period. A total of 601 of 803 consecutively eligible men were included.

interventionsAll men were offered prebiopsy MRI and assigned a maximum MRI suspicion score (mSS). Men with an MRI abnormality underwent combined MRF-TB and SB. OUTCOMES: Detection rates for all PCa and high-grade PCa (Gleason score [GS] ≥7) were compared using the McNemar test. RESULTS AND LIMITATIONS: MRF-TB detected fewer GS 6 PCas (75 vs 121; p<0.001) and more GS ≥7 PCas (158 vs 117; p<0.001) than SB. Higher mSS was associated with higher detection of GS ≥7 PCa (p<0.001) but was not correlated with detection of GS 6 PCa. Prediction of GS ≥7 disease by mSS varied according to biopsy history. Compared to SB, MRF-TB identified more GS ≥7 PCas in men with no prior biopsy (88 vs 72; p=0.012), in men with a prior negative biopsy (28 vs 16; p=0.010), and in men with a prior cancer diagnosis (42 vs 29; p=0.043). MRF-TB detected fewer GS 6 PCas in men with no prior biopsy (32 vs 60; p<0.001) and men with prior cancer (30 vs 46; p=0.034). Limitations include the retrospective design and the potential for selection bias given a referral population.

conclusionsMRF-TB detects more high-grade PCas than SB while limiting detection of GS 6 PCa in men presenting for prostate biopsy. These findings suggest that prebiopsy multiparametric MRI and MRF-TB should be considered for all men undergoing prostate biopsy. In addition, mSS in conjunction with biopsy indications may ultimately help in identifying men at low risk of high-grade cancer for whom prostate biopsy may not be warranted. PATIENT SUMMARY: We examined how magnetic resonance imaging (MRI)-targeted prostate biopsy compares to traditional systematic biopsy in detecting prostate cancer among men with suspicion of prostate cancer. We found that MRI-targeted biopsy detected more high-grade cancers than systematic biopsy, and that MRI performed before biopsy can predict the risk of high-grade cancer.

Indexed as

Magnetic Resonance ImagingMagnetic Resonance Imaging, InterventionalUltrasonography, InterventionalAgedHumansImage-Guided BiopsyMaleMiddle AgedNeoplasm GradingPredictive Value of TestsProstatic NeoplasmsReproducibility of ResultsRetrospective StudiesRisk FactorsMagnetic resonance imaging–targeted prostate biopsyMagnetic resonance imaging-ultrasound fusionProstate biopsyProstate cancerProstate magnetic resonance imaging

Identifiers

PMID26112001
PMCPMC5104338
OpenAlexW778629108

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.